Immunomedics reports epratuzumab with chemo beneficial to leukemia treatment Immunomedics announced that adult patients with relapsed or refractory acute lymphocytic leukemia reported a complete response rate of 50% after receiving one cycle of treatment with epratuzumab in combination with the chemotherapy agents, clofarabine and cytarabine. Results from this Phase II S0910 study conducted by the Southwest Oncology Group of the National Cancer Institute were presented at the 2012 Annual Meeting of the American Society of Hematology by Anjali S. Advani, MD, Principal Investigator. Southwest Oncology Group had previously reported a complete response rate of 17% in adult patients with ALL using only the combination of clofarabine and cytarabine. Because virtually all immature B cells express CD22, which is the target of the company's proprietary humanized antibody, epratuzumab, the NCI-study group wanted to evaluate the CR rate of combining the anti-CD22 antibody with the two chemotherapeutic agents.
News For IMMU From The Last 14 Days
Check below for free stories on IMMU the last two weeks.